Hypertension drug boosts Actelion’s revenues in 2008 third quarter

Actelion AG, the Swiss biopharmaceutical company, reported higher third quarter sales and earnings largely as a result of expanding sales of Tracleer (bosentan), its treatment for pulmonary arterial hypertension (PAH).